| [1] |
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics，2021[J]．CA Cancer J Clin, 2021，71(1)：7-33.
|
| [2] |
孙永辉，陶维阳．乳腺癌前哨淋巴结活检研究进展[J]．现代肿瘤医学，2017，25(4)：634-637.
|
| [3] |
贺新伟，王学中．前哨淋巴结活检与腋窝淋巴结清扫术在早期乳腺癌患者的应用对比[J]. 中国全科医学，2017，20(S1): 63-65.
|
| [4] |
Cserni G，Chmielik E，Cserni B，et al. The new TNM-based staging of breast cancer[J]. Virchows Arch，2018，472(5)：697-703.
|
| [5] |
Euscher ED，Malpica A，Atkinson EN，et al. Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma[J]. Am J Surg Pathol，2008，32(9)：1336-1343.
|
| [6] |
Cotarelo CL, Zschöck-Manus A, Schmidt M, et al. Improved detection of sentinel lymph node metastases allows reliable intraoperative identification of patients with extended axillary lymph node involvement in early breast cancer[J]. Clin Exp Metastasis, 2021，38(1)：61-72.
|
| [7] |
Weaver DL, Krag DN，Manna EA, et al. Detection of occult sentinel lymph node micrometastases by immunohistochemistry in breast cancer. An NSABP protacol B-32 quality assurance study [J]. Cancer, 2006，107(4)：661-667.
|
| [8] |
Jaffer S, Nagi C, Bleiweiss IJ. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node negative patients with 20-year follow-up[J]. Adv Anat Pathol, 2008，15(6)：370-373.
|
| [9] |
王立军，唐蔚，李智宇，等．乳腺癌腋窝淋巴结微转移的预后与治疗探讨[J]. 医学研究杂志，2020，49(1)：41-46.
|
| [10] |
Hintzen KFH, de Rooij L, Schouten N, et al. Molecular analysis of sentinel lymph nodes in patients with breast cancer using one-step nucleic acid amplification (OSNA): Does not lead to overtreatment in the current era of de-escalating axillary management[J]. Surg Oncol，2020，35：224-228.
|
| [11] |
练斌，覃庆洪，杨伟萍，等．彩色多普勒超声对乳腺癌前哨淋巴结微转移的诊断价值[J]. 广西医科大学学报，2016，33(5)：783-786.
|
| [12] |
Le Boulc’h M, Gilhodes J, Steinmeyer Z, et al. Pretherapeutic imaging for axillary staging in breast cancer: a systematic review and meta-analysis of ultrasound, MRI and FDG PET[J]. J Clin Med，2021，10(7)：1543.
|
| [13] |
van Rijk C，Peterse L，Nieweg E，et al. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submi-crometastases in sentinel lymph nodes[J]. Cancer，2006，107(3)：467-471.
|
| [14] |
van Deurzen CH，van Hillegersberg R，Hobbelink MG，et al. Predictive value of tumor load in breast cancersentinel lymph nodes for second echelon lymph node metastases[J]. Cell Oncol，2007，29(6)：497-505.
|
| [15] |
van la Parra RF, Peer PG, Ernst MF，et al. Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive SLN[J]. Eur J Surg Oncol，2011，37(4)：290-299.
|
| [16] |
Boler DE，Uras C，Ince U，et al. Factors predicting the non-sentinel lymph node involvement in breast cancer patients with sentinel lymph node metastases[J]. Breast，2012，21(4)：518-523.
|
| [17] |
Houvenaeghel G, Cohen M, Raro P, et al. Overview of the pathological results and treatment characteristics in the first 1000 patients randomized in the SERC trial: axillary dissection versus no axillary dissection in patients with involved sentinel node[J]. BMC Cancer，2018，18(1)：1153.
|
| [18] |
李毓冰. 前哨淋巴结阳性乳腺癌患者非前哨淋巴结转移风险预测模型研究[D]．沈阳：中国医科大学，2021.
|
| [19] |
Lale A, Yur M, Özgül H, et al. Predictors of non-sentinel lymph node metastasis in clinical early stage (cT1-2N0) breast cancer patients with 1-2 metastatic sentinel lymph nodes[J]. Asian J Surg，2020，43(4)：538-549.
|
| [20] |
de Boer M，Van Dijck A，Bult P，et al. Breast cancer prognosis and occult lymph node metastases，isolated tumor cells，and micrometastases[J]. J Natl Cancer Inst，2010，102(6)：410-425.
|
| [21] |
Andersson Y, Frisell J, Sylvan M，et al. Breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes[J]. J Clin Oncol，2010，28(17)：2868-2873.
|
| [22] |
Bae HW, Yoon KH, Kim JH, et al. Impact of micrometastatic axillary nodes on survival of breast cancer patients with tumors ≤2 cm[J]. World J Surg，2018，42(12)：3969-3978.
|
| [23] |
Houvenaeghel G，Classe M，Garbay R, et al. Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer：aFrench sentinel node multicenter cohort study[J]. Breast，2014, 23(5)：561-566.
|
| [24] |
Hetterich M, Gerken M, Ortmann O, et al. Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases[J]. Breast Cancer Res Treat，2021，187(3)：715-727.
|
| [25] |
Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial[J]. JAMA，2017，318(10)：918-926.
|
| [26] |
Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinelnode micrometastases (IBCSG 23- 01)：10- year follow- up of a randomised, controlled phase 3 trial[J]. Lancet Oncol，2018，19 (10)：1385-1393.
|
| [27] |
Solá M, Alberro JA, Fraile M, et al.Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node icrometastasis: final results from the multicenter clinical trial AATRM048/13/2000[J]. Ann Surg Oncol，2013，20(1)：120-127.
|
| [28] |
Lim SZ, Kusumawidjaja G, Mohd Ishak HM, et al. Outcomes of stage Ⅰ and Ⅱ breast cancer with nodal micrometastases treated with mastectomy without axillary therapy[J]. Breast Cancer Res Treat, 2021，189(3)：837-843.
|
| [29] |
Andersson Y, Bergkvist L, Frisell J, et al. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial[J]. Br J Surg，2021，108(9)：1105-1111.
|
| [30] |
Pepels MJ，de Boer M，Bult P，et al.Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells[J]. Ann Surg，2012，255(1): 116-121.
|
| [31] |
Wu SP, Tam M, Shaikh F, et al. Post-mastectomy radiation therapy in breast cancer patients with nodal micrometastases[J]. Ann Surg Oncol，2018，25(9)：2620-2631.
|
| [32] |
Patel M, Li C, Aronson JH, Howie CM, et al. The effect of post mastectomy radiation therapy on survival in breast cancer patients with N1mic disease[J]. Breast，2020，51：50-56.
|
| [33] |
Luo H, Yang OO, He JL，et al. Impact of post-mastectomy radiation therapy for sentinel lymph node micrometastases in early-stage breast cancer patients[J]. Med Sci Monit，2022，28：e933275.
|
| [34] |
Hetterich M, Gerken M, Ortmann O, et al. Adjuvant chemotherapy for breast cancer patients with axillary lymph node micrometastases[J]. Breast Cancer Res Treat，2021，187(3)：715-727.
|
| [35] |
Gradishar WJ, Moran MS, Abraham J, et al. NCCN guidelines? insights: breast cancer, version 4.2021[J]. J Natl Compr Canc Netw，2021，19(5)：484-493.
|
| [36] |
中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳腺癌诊治指南与规范(2021年版)[J]．中国癌症杂志，2021，31(10)：954-1040.
|
| [37] |
Huang TT, Chen AC, Lu TP，et al. Clinical-genomic models of node-positive breast cancer: training, testing, and validation[J]. Int J Radiat Oncol Biol Phys，2019，105(3)：637-648.
|
| [38] |
Zhang L, Zhou M, Liu Y, et al. Is it beneficial for patients with pT1-2N1M0 breast cancer to receive postmastectomy radiotherapy? An analysis based on RecurIndex assay[J]. Int J Cancer，2021，149(10)：1801-1808.
|
| [39] |
Wong SM, Almana N, Choi J, et al. Prognostic significance of residual axillary nodal micrometastases and isolated tumor cells after neoadjuvant chemotherapy for breast cancer[J]. Ann Surg Oncol，2019，26(11)：3502-3509.
|
| [40] |
Canavese G, Tinterri C, Carli F, et al. Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients[J]. Eur J Surg Oncol，2021，47(8)：1920-1927.
|
| [41] |
van Nijnatten TJ, Simons JM, Moossdorff M, et al. Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumor cells and micrometastases carry a better prognosis than macrometastases[J]. Breast Cancer Res Treat，2017，163(1)：159-166.
|
| [42] |
Chun JW, Kim J, Chung IY, et al. Sentinel node biopsy alone for breast cancer patients with residual nodal disease after neoadjuvant chemotherapy[J]. Sci Rep，2021，11(1)：9056.
|
| [43] |
Kantor O, Wong S, Weiss A, et al. Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer[J]. NPJ Breast Cancer，2020，6：35.
|